Jian Ai Shi Biopharmaceutical Technology

JianAiShi Biopharmaceutical Technology is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of innovative therapies for autoimmune and inflammatory diseases. The company focuses on creating oral alternatives to injectable biologics, particularly targeting the IL-17 pathway to treat conditions such as psoriasis and ankylosing spondylitis. Their lead candidate, JAS-101, is an orally available small molecule inhibitor designed to provide the efficacy of monoclonal antibodies with the convenience of oral administration. JianAiShi leverages a proprietary drug discovery platform to optimize the metabolic stability and bioavailability of its pipeline candidates.